MAPP BIOPHARMACEUTICAL, INC. — Department of Health and Human Services SBIR Phase II: R

Description

DESCRIPTION provided by applicant Staphylococcal enterotoxin B SEB Category B agent a toxin that commonly causes classic food poisoning and can cause a non menstrual toxic shock syndrome TSS has been studied as a potential biological warfare agent Importantly SEB is derived from common readily accessible bacteria is relatively easily produced and can be delivered in a stable aerosol form SEB exhibits severe toxicity by the inhalation route once inhaled it causes widespread systemic damage multi organ system failure and even shock and death at microgram doses Clearly an SEB attack would be devastating to civilian populations as well as on the battlefield during times of war Currently there are no preventatives or therapeutics available against SEB Monoclonal antibodies mAbs are a class of FDA approved biologics that can potently neutralize toxins Because of their stability specificity versatility and low potential for immunogenicity mAbs are ideal for biodefense related countermeasures As a result of successful completion of our Phase efforts we have identified a highly potent mAb that protects mice from systemic and aerosol challenge Further in this proposal we are combining forces with Integrated Biotherapeutics Gaithersburg MD whose team has identified an additional anti SEB mAb via separate NIAID funding Together we will determine which of the two mAbs is the most appropriate for continued development resulting in cost savings for NIH The Long Range Objective of this project is to develop a safe and effective immunoprotectant product for SEB We expect the initial indication will be for pre and post exposure prophylaxis The Specific Aims and Milestones of this proposal are Aim Produce the two candidate mAbs using a Nicotiana benthamiana based rapid antibody manufacturing platform RAMP Aim Evaluate the pre and post exposure efficacy of the two mAbs in non human primates against aerosolized SEB The most efficacious mAb to be designated MB SEB will be chosen for continued development Aim Complete Investigational New Drug IND enabling studies to prepare for clinical evaluation of MB SEB in accordance with regulatory requirements Using RAMP mAb produced under Good Manufacturing Practice GMP the studies necessary pharmacology and toxicology chemistry manufacturing and control data to submit an IND application will be performed to support a Phase safety trial PUBLIC HEALTH RELEVANCE The efforts in this proposal will help in the development of a drug for preventing and treating exposure to SEB a highly potent toxin that is a significant biological warfare threat to public and military safety